Phase IIIb, Open-label study evaluating the efficacy and safety of luspatercept BMS-986346/ACE-536 initiated at maximum approved dose in LR-MDS with IPSS-R very low, low or intermediate risk who require RBC transfusions MAXILUS

Brief Summary

Type:
Myelodysplastic Syndrome

Study Type:
Treatment

Phase:
III

ClinicalTrials.gov Identifier:
NCT06045689

Study #:
STUDY00160164

Start Date:
May 07, 2024

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT06045689

View Complete Trial Details & Eligibility at ClinicalTrials.gov